Endocrine Abstracts

Materials and methods: The study included 58 patients (50 female, 8 males) aged from 38 to 60 years, have received surgical treatment for GD with the period of follow-up after treatment for 2 to 10 years. The patients were divided into 2 groups depending on the initial level of TSH. In the first group (33 persons) included patients with low-normal level of TSH (0.4–2.5 mU/ml), the in second group (25 persons) with upper-normal level of TSH (2.6–4.0 mU/ml). Quality of life was assessed with the help of the using the questionnaire Short-Form SF-36.

Results: In the first group the median age of patients was 43 years (35;50),median follow-up after treatment 7 years (5;10), the average level of TSH 1.8 mU/ml (1.55;2.3), a median dose of L-T4 100 mcg (100;125), the median quality of life of 8 scales questionnaire SF -36 ranged from 54 points (vitality) up to 85 (pain).

In the second group the median age was 56 years (49;64), the median follow-up after treatment of 8 years (7;10), the average level of TSH 3.8 mU/ml (3.2;4), a median dose of L-T4 75 mcg (75;100), the median quality of life of 8 scales ranged from 40 points (vitality) to 58 (physical functioning).

In the evaluation of mean values of the quality of life in the first and second group, statistically significant differences were observed on all scales (P<0.05).

Conclusions: The average quality of life of patients were on average and high level, however, there are significant differences in quality of life among patients with upper- and low-normal TSH. It is established that patients with upper-normal TSH had the worst performance, in the course of our study revealed a statistically significant difference between all scales.

Declaration of interest: The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research project.

Funding: This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector